[특징주] Ildong Pharmaceutical’s success in the production of failed Alzheimer’s treatments in Switzerland and China is on the rise

Ildong Pharmaceutical is on the rise in the news that companies such as Swiss Lonza, the United States, China, and Taiwan have all succeeded in producing’iCP-Parkin’, a new drug for treating Alzheimer’s and Parkinson’s disease, which failed to produce.

As of 1:42 pm on the 2nd, Ildong Pharmaceutical is trading at 17900 won, up 750 won (4.37%) from the previous day. Sellybury, a joint developer of Ildong Pharmaceutical and iCP-Parkin, surged 23.43%.

On this day, Ildong Pharmaceutical Co., Ltd. and iCP-Parkin co-developer, Cellibury, announced that they had succeeded in producing new drugs to treat Parkinson’s disease and Alzheimer’s disease.

iCP-Parkin attempted to produce non-clinical and clinical samples at Lonza (Visff), the world’s best commissioned production organization, but the protein structure was unstable, and it was difficult to establish a process necessary for mass production, and eventually failed to produce it.

In order to solve this problem, PBI (Oregon, Oregon) in the United States carried out the production process of this recombinant protein with high-pressure technology, but again, a problem of forming a multimer was discovered and the problem of formation of a multimer was not solved. Failed.

Since then, Taiwan’s global production organization Genovior (Miaori), China’s Gene Universal (Nanjing), and South Korea’s commissioned production institutions have also attempted mass production of clinical samples, but all of them are known to have failed.

In response to this news, it is interpreted that the stock market is rising due to the rush of buying from Sellybury and Ildong Pharmaceutical.

Ildong Pharmaceutical has secured 40% equity rights through direct investment in’iCP-Parkin’ and is developing jointly with Sellybury.

At the beginning of this year, Ildong Pharmaceutical participated in the JP Morgan Healthcare Conference and participated in’iCP-Parkin’ as well as metabolic disease treatment △ liver disease treatment △ eye disease treatment △ solid cancer treatment type 2 diabetes treatment new drug candidate’IDG-16177′ and non-alcoholic. Research projects for new drugs such as’ID11903′, a treatment for steatohepatitis, and related candidates have been disclosed.